Monoclonal Antibody to Aspartate Beta Hydroxylase (ASPH)
| Code | Size | Price |
|---|
| MAG151Hu22-20ul | 20ul | £92.00 |
Quantity:
| MAG151Hu22-100ul | 100ul | £173.00 |
Quantity:
| MAG151Hu22-200ul | 200ul | £234.00 |
Quantity:
| MAG151Hu22-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
BAH; CASQ2BP1; HAAH; JCTN; Junctin; Humbug; Junctate; Aspartyl/Asparaginyl Beta-Hydroxylase; Peptide-aspartate beta-dioxygenase
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Aspartate Beta Hydroxylase
Potency (Clone Number):
C12
Reactivity:
Po;
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.2-2ug/mL;1:500-5000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Aspartate Beta Hydroxylase (ASPH) | RPG151Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||